Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topical lidocaine vs placebo for pain during dual-target subcutaneous injection in HER2-positive breast cancer
ChiCTR2600122608Phase 2Not yet recruiting
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of lidocaine in breast cancer (2 arms), sponsored by Jiangsu Provincial People's Hospital. Primary endpoint: Pain score during dual-target subcutaneous injection (VAS). Planned start Apr 2026; status: not yet recruiting.
02
Drugs
lidocaine
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR2600122608.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600122608.